Doctors and scientists at Massachusetts General Hospital and Hackensack University Medical Center will join teams at the National Cancer Institute and Washington University at St Louis in helping evaluate the cell therapy.
The treatment will be used to combat difficult relapsed or refractory ovarian cancer and malignant peritoneal mesothelioma, which affects the lining of the abdomen.
The new teams will administer MCY-M11 via the peritoneum and patients will receive what’s called a preconditioning regimen consisting of a chemotherapy called cyclophosphamide.
MaxCyte expanded the phase I clinical assessment after unveiling “encouraging preliminary results” from the study in May.
Preliminary clinical data from the earlier patient groups are expected sometime in the second half of this year.
“We are very pleased with the progress of this first-in-human trial to date, and have great hopes that we are moving closer towards bringing a more effective immunotherapeutic option for patients with solid tumours,” said Claudio Dansky Ullmann, chief medical officer of MaxCyte.